尖端的降脂药理疗法:改善超越他类药物的脂质控制
M Capuozzo1, A Ottaiano2, C Cinque1
1Hospital Pharmacist Manager, Pharmaceutical Department, Asl Napoli 3 Sud., Italy.
Hipertension y riesgo vascular
|January 7, 2025
概括
新型降脂疗法 (LLT),如佩多酸和PCSK9抑制剂,为治疗动脉样硬化心血管疾病 (ASCVD) 和失脂症提供了新的选择,特别是在对他类药物不耐受的患者中.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 药物是动脉样硬化心血管疾病 (ASCVD) 的主要治疗方法,但残留风险仍然存在.
- 需要新的降脂疗法 (LLT) 来进一步降低低密度脂蛋白胆固醇 (LDL-C) 和异构脂蛋白.
- 失脂症的管理需要创新的方法超越传统的他类药物治疗.
研究的目的:
- 审查新兴的LLT,重点关注佩多酸和PCSK9抑制剂.
- 检查这些新型药物的作用机制和临床疗效.
- 突出其在治疗脱脂症和降低心血管风险方面的潜在作用.
主要方法:
- 关于bempedoic酸和PCSK9抑制剂的当前文献的综述.
- 对它们针对胆固醇生物合成和LDL受体通路的机制的分析.
- 评估临床试验数据的疗效和安全性.
主要成果:
- 班佩多酸抑制ATP酸酶,为他类药物不耐受患者提供了替代方案.
- PCSK9抑制剂增强了LDL受体循环,显著降低了LDL-C水平.
- 新兴的反感性寡核酸表明,它有望准特定的异构分子.
结论:
- 佩多酸和PCSK9抑制剂代表了LLT的重大进展.
- 这些药物为患有脱脂症和高心血管风险的患者提供了有价值的治疗选择.
- 对新型LLT的进一步研究,包括针对apoC3,ANGPTL3和脂蛋白的研究正在进行中.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
464
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
464
Diabetes: Management and Pharmacotherapy
203
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
203
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
384
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
384
Glucagon-like Receptor Agonists
249
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
249
Adrenergic Antagonists: ɑ and β-Receptor Blockers
374
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
374
Drug Therapy
21
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
21


